Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339359 | 0.87 | OPRL1 (0.39) | OPRL1OPRM1OPRD1OPRK1DRD2 | |
| SCHEMBL13914015 | 0.85 | DRD2 (0.55) | OPRL1OPRM1OPRD1OPRK1DRD2 | |
| SCHEMBL4322410 | 0.84 | OPRL1 (0.62) | OPRL1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL4318199 | 0.82 | OPRM1 (0.53) | OPRL1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL4324265 | 0.80 | OPRL1 (0.50) | OPRL1OPRM1MAPTDRD2DRD4 | |
| SCHEMBL4329472 | 0.80 | OPRL1 (0.55) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4332755 | 0.80 | OPRL1 (0.56) | OPRL1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL4331687 | 0.79 | EGLN1 (0.48) | MAPT | |
| SCHEMBL8259826 | 0.79 | MAPT (0.44) | MAPT | |
| SCHEMBL4324271 | 0.79 | ALDH1A1 (0.48) | MAPTDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | OPRL1 96/4885OPRM1 264/4885OPRD1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.